Ibruxen 140 MG (Ibrutinib)

Basic Product Information of Ibruxen 140 MG (Ibrutinib)

How Ibruxen 140 MG Works Covalent BTK Inhibition and BCR Signalling Blockade

Ibrutinib, the active ingredient in Ibruxen 140 MG, is a first-in-class, small-molecule, covalent Bruton’s tyrosine kinase (BTK) inhibitor that targets BTK the critical non-receptor tyrosine kinase positioned immediately downstream of the B-cell antigen receptor (BCR) and cytokine receptor signalling networks. Ibrutinib forms a selective, irreversible covalent bond with the cysteine-481 (Cys481) residue in the ATP-binding domain of BTK, permanently inactivating BTK kinase activity in each exposed B-cell. Because this bond is irreversible, recovery of BTK signalling depends entirely on de novo BTK protein synthesis rather than drug dissociation, producing sustained suppression of BCR signalling that outlasts the plasma half-life of ibrutinib itself. Malignant B-cell lineages most dependent on constitutive BTK activity including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenström’s macroglobulinemia (WM), marginal zone lymphoma (MZL), and certain B-cell non-Hodgkin lymphomas are characterised by pathological amplification of BCR signalling that ibrutinib dismantles at its primary intracellular node.

Ibrutinib’s covalent BTK blockade prevents activation of multiple downstream oncogenic signalling cascades including PLCγ2-mediated calcium mobilisation, PI3K/AKT-mediated pro-survival signalling, NF-κB transcriptional activation, and ERK-mediated proliferative signalling. Collectively, these effects abolish the BCR-driven proliferation, survival, and homing signals that sustain malignant B-cells within the bone marrow and lymph node microenvironments. Ibrutinib additionally disrupts integrin-mediated adhesion and CXCL12/CXCR4 chemotactic signalling, which mobilises malignant B-cells out of protective bone marrow and lymph node niches into the peripheral circulation a pharmacological effect that initially elevates the peripheral lymphocyte count (treatment-related lymphocytosis) before B-cell elimination proceeds, and which haematologists must distinguish from true disease progression. A key clinical advantage of ibrutinib is its efficacy in del(17p) and TP53-mutated CLL the highest-risk cytogenetic subgroup in which chemoimmunotherapy produces minimal durable responses because ibrutinib’s BCR signalling mechanism is entirely independent of p53-mediated apoptotic pathways. Haematologists managing patients across the full spectrum of B-cell malignancies can source Ibruxen 140 MG alongside comprehensive haematology and oncology agents through Mediaid Pharmacy’s oncology medicines catalogue.

In the landmark RESONATE-2 trial in treatment-naive CLL patients aged ≥65 years, ibrutinib reduced the risk of disease progression or death by 84% versus chlorambucil (hazard ratio 0.161, p<0.001), with a median progression-free survival (PFS) that was not reached for ibrutinib versus 18.9 months for chlorambucil; the overall response rate (ORR) was 86% versus 35%. In the RESONATE trial in relapsed or refractory CLL and SLL, ibrutinib reduced the risk of progression or death by 88% versus ofatumumab (HR 0.145, p<0.001) and reduced the risk of death by 43% (OS HR 0.434). In the RAY trial in relapsed or refractory mantle cell lymphoma, ibrutinib achieved a median PFS of 14.6 months versus 6.2 months for temsirolimus (HR 0.43, p<0.0001) with an ORR of 72% versus 40%. In the iNNOVATE trial in Waldenström’s macroglobulinemia, ibrutinib plus rituximab produced a major response rate of 72% versus 32% for rituximab alone (p<0.0001) with a 30-month PFS rate of 82% versus 28% (HR 0.20).

Approved Indications for Ibruxen 140 MG (Ibrutinib)

Ibruxen 140 MG (Ibrutinib) is indicated across five distinct B-cell malignancy and immune disease settings where covalent BTK inhibition delivers clinically significant, durable outcomes:

Key Clinical Benefits of Ibruxen 140 MG (Ibrutinib)

How to Take Ibruxen 140 MG (Ibrutinib) Dosage Guidelines

Clinical Monitoring Requirements During Ibruxen (Ibrutinib) Treatment

Systematic clinical monitoring is mandatory before initiating and throughout the course of Ibruxen (Ibrutinib) treatment. Before starting therapy, haematologists must assess baseline complete blood count (CBC) with differential, comprehensive metabolic panel including liver function tests (ALT, AST, bilirubin, alkaline phosphatase), renal function (serum creatinine, eGFR), cardiac history (atrial fibrillation or flutter, valvular heart disease, prior cardiac events), blood pressure, and bleeding history. Ibrutinib is not recommended in patients with severe hepatic impairment (Child-Pugh C); patients requiring anticoagulation with warfarin or other vitamin K antagonists require careful assessment, as the combination increases haemorrhagic risk and warfarin must not be co-administered with ibrutinib per many institutional protocols.

During treatment, complete blood counts are performed monthly or more frequently during the first 6 months and every 1–3 months thereafter; Grade 3–4 neutropenia or thrombocytopenia requires dose interruption per the dose modification guidelines. Blood pressure must be monitored throughout therapy, as Grade 3 or higher hypertension has been reported in up to 17% of ibrutinib-treated patients; antihypertensive therapy should be initiated promptly when indicated. Cardiac rhythm monitoring with 12-lead ECG is performed at baseline in patients with pre-existing cardiac risk factors, and immediately in any patient who develops new-onset palpitations, dyspnoea, or presyncope during ibrutinib treatment, as atrial fibrillation and flutter occur in up to 11% of patients and require prompt cardiological evaluation and management. Liver function tests are assessed monthly for the first 3 months and periodically thereafter; dose modification or discontinuation is required for significant hepatotoxicity. Treatment-related lymphocytosis a transient, reversible rise in circulating CLL or MCL cells during the first 1–3 months of ibrutinib therapy due to mobilisation of malignant B-cells from lymphoid tissue must be monitored and distinguished from progressive disease; lymphocytosis alone, without other signs of progression, does not warrant treatment discontinuation. Patients must avoid elective surgery for at least 3–7 days before and after ibrutinib therapy to minimise peri-operative bleeding risk.

Drug Interactions and Important Safety Information for Ibruxen (Ibrutinib)

Strong CYP3A4 inhibitors including ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, ritonavir, indinavir, cobicistat, and grapefruit/grapefruit juice substantially increase ibrutinib plasma exposure and must be avoided during Ibruxen treatment wherever clinically possible. When short-term co-administration with a strong CYP3A4 inhibitor cannot be avoided, the Ibruxen dose must be reduced to 140 mg once daily (one capsule) with clinical vigilance for toxicity amplification; the indication-appropriate dose is resumed 2–3 days after the inhibitor is discontinued. Strong CYP3A4 inducers including rifampicin, carbamazepine, phenytoin, phenobarbital, and St. John’s Wort (Hypericum perforatum) reduce ibrutinib plasma concentrations by up to 10-fold and must be strictly avoided throughout the course of Ibruxen therapy; where an anti-infective is required, rifabutin has a substantially lower CYP3A4 induction potential and may be considered as an alternative. Moderate CYP3A4 inhibitors including diltiazem, verapamil, dronedarone, erythromycin, and fluconazole require an ibrutinib dose reduction to 280 mg once daily (two capsules); resume the prior dose 2–3 days after discontinuation.

Ibrutinib inhibits P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) at clinically relevant concentrations. Co-administration with P-gp or BCRP substrates with a narrow therapeutic index including digoxin, colchicine, topotecan, and methotrexate may increase the plasma concentrations and toxicity risk of these agents; administer the P-gp or BCRP substrate at least 6 hours before ibrutinib and monitor for toxicity. Anticoagulant and antiplatelet agents substantially increase the risk of haemorrhage when combined with ibrutinib; warfarin and other vitamin K antagonists must not be co-administered with ibrutinib per the prescribing reference label; antiplatelet agents including aspirin, clopidogrel, and NSAIDs carry additive haemorrhagic risk and should be used only when the clinical benefit clearly outweighs the bleeding hazard, with active monitoring. Proton pump inhibitors (PPIs) reduce ibrutinib absorption; where acid suppression is required, H2 receptor antagonists taken at least 2 hours before or 10 hours after ibrutinib are preferred over PPIs. All patients must disclose all medications, over-the-counter agents, herbal supplements, and dietary habits particularly grapefruit consumption to their haematologist before starting Ibruxen therapy.

Side Effects and Precautions of Ibruxen 140 MG (Ibrutinib)

Who Should Use Ibruxen 140 MG (Ibrutinib)?

Ibruxen 140 MG (Ibrutinib) is indicated for adult patients across five haematologic malignancy and immune disease settings: adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in both the treatment-naive and relapsed or refractory settings, including those with del(17p) or TP53 mutation; adults with relapsed or refractory mantle cell lymphoma (MCL) after at least one prior therapy; adults with Waldenström’s macroglobulinemia (WM) treatment-naive or relapsed; adults with relapsed or refractory marginal zone lymphoma (MZL) after at least one prior anti-CD20-based regimen; and adult patients with chronic graft-versus-host disease (cGVHD) after failure of one or more prior systemic therapies. Patients must have confirmed histological diagnosis of the relevant B-cell malignancy or donor-derived cGVHD assessment prior to initiating Ibruxen therapy. Patients with a prior history of atrial fibrillation, cardiac failure, uncontrolled hypertension, active major bleeding, or severe hepatic impairment require individualized benefit-risk assessment by the prescribing haematologist before Ibruxen initiation. Ibruxen is prescribed exclusively by haematologists and medical oncologists with expertise in B-cell malignancy management and BTK inhibitor therapy. For institutions and healthcare distributors requiring a complete portfolio of targeted haematology and oncology treatments including CD20 antibodies, venetoclax, PI3K inhibitors, and immunomodulatory agents used alongside ibrutinib in CLL, MCL, WM, and MZL Mediaid Pharmacy’s oncology specialty medicines portfolio provides a comprehensive range of precision cancer treatments sourced from verified international manufacturers.

Global Supplier: Mediaid Pharmacy Worldwide Shipping for Ibruxen 140 MG (Ibrutinib)

Mediaid Pharmacy is a trusted global supplier of specialty oncology and targeted haematology medications, supplying Ibruxen 140 MG (Ibrutinib) with reliable worldwide shipping to South Asia, the Middle East, Africa, Southeast Asia, Europe, and beyond. Ibruxen 140 MG is registered in Bangladesh and supplied in a 120-capsule pack, providing a full 30-day dispensing cycle for MCL and MZL patients at 560 mg daily, and a 40-day supply for CLL, WM, and cGVHD patients at 420 mg daily. Our specialist team provides complete order support including pricing quotations, stock availability confirmation, regulatory and import documentation, and end-to-end international delivery tracking. Contact Mediaid Pharmacy directly via WhatsApp, phone, or WeChat for all enquiries regarding Ibruxen 140 MG (Ibrutinib) availability, pricing, and international delivery to your country.

Why Choose Ibruxen 140 MG (Ibrutinib) from Mediaid Pharmacy?

Ibruxen 140 MG represents a clinically proven and globally accessible ibrutinib formulation for patients with CLL/SLL, MCL, WM, MZL, and cGVHD five haematologic malignancy and immune disease indications for which ibrutinib has demonstrated statistically significant, clinically meaningful response rates and survival improvements across multiple randomised phase III trials including RESONATE, RESONATE-2, RAY, and iNNOVATE. The 120-capsule Ibruxen pack is specifically designed to cover the complete dosing requirements of all approved ibrutinib indications: it provides an exact 30-day supply for MCL and MZL patients at 560 mg daily (4 capsules/day × 30 days = 120 capsules) and a 40-day supply for CLL, WM, and cGVHD patients at 420 mg daily (3 capsules/day × 40 days = 120 capsules) minimising dispensing gaps and supporting uninterrupted continuity of daily oral therapy. A single 140 mg capsule strength executed across the full ibrutinib dose range (140 mg for strong CYP3A4 inhibitor co-administration, 280 mg for moderate CYP3A4 inhibitor co-administration, 420 mg for CLL/WM/cGVHD, and 560 mg for MCL/MZL) simplifies both dispensing and dose modification management without requiring multiple capsule strengths or tablet splitting. Distributed globally by Mediaid Pharmacy with worldwide shipping, Ibruxen 140 MG gives patients and haematology teams in both established and emerging healthcare markets access to the first-in-class, covalent BTK inhibitor that transformed the treatment landscape across all major B-cell malignancies. For oncology centres and importers requiring a full range of B-cell malignancy therapeutics and targeted oncology agents, Mediaid Pharmacy’s oncology medicines section provides a complete portfolio of specialty cancer treatments sourced from verified manufacturers. For any haematologist or oncology institution seeking a proven, accessible, and precisely dosed ibrutinib option, Ibruxen 140 MG from Mediaid Pharmacy is the trusted clinical choice.

Frequently Asked Questions About Ibruxen 140 MG (Ibrutinib)